Status:
COMPLETED
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Renal Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- metastatic RCC with majority (\>50%) of conventional clear-cell type;
- prior total nephrectomy for primary RCC;
- at least one measurable or non-measurable lesions;
- ECOG performance score of 0 or 2.
Exclusion
- prior systemic treatment for metastatic RCC;
- current or previously treated but non-stable CNS metastases or spinal cord compression;
- major surgery (including open biopsy) or radiation therapy within 28 days prior to enrollment;
- significant cardiovascular disease within 6 months prior to enrollment.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT00796757
Start Date
December 1 2008
End Date
February 1 2012
Last Update
May 27 2015
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Olomouc, Czechia, 775 20
2
Prague, Czechia, 128 08
3
Tallinn, Estonia, 10617
4
Tallinn, Estonia, 13419